UNASSIGNED: e15590 Background: To evaluate the safety and efficacy of bevacizumab ( @entity1493 ) alone or combined with chemotherapy (CT) in a compassive use program sponsored by the Spanish @entity43 Research Group (GEICO). METHODS: 92 @entity1 (pts) with relapsed @entity43 who were not candidates for standard therapy received @entity1493 alone (n=43) or @entity1493 +CT (n=49) from Mar'06 to Dec'09. @entity137 , response rate (RR), overall survival (OS) and progression-free survival (PFS) median (med) time from @entity1493 treatment to last follow-up, were analyzed. RESULTS: Med age was 56 (24-85) years, and main histologies were papillary-serous/endometroid/clear-cell/undifferentiated (n, 62/8/1/8), mostly graded 1-2 (n=69). Pts had received a med of 4 (1-9) lines prior to @entity1493 and a med of 2 (0-4) surgeries. Prior @entity902 agents had been administrated to all pts, being resistant (PR, < 6 mo) n=23; partially sensitive (PPS, 6-12 mo) n=32; or sensitive (PS, > 12 mo) n=37. Most pts had peritoneal+pelvic (n=51) or hepatic (n=22) involvement at last progression, with >1 site (n=78). @entity1493 was given at 15 mg/kg every 3 wk (q3w; n=43), 10 mg/kg q2w (n=46) or 5 mg/kg q2w (n=3), and, when combined, @entity1311 (n=13), @entity1945 (n=12), and @entity786 (n=10) were the most frequent CT agents used. Main grade 3-4 @entity137 were @entity1398 (n=5), @entity417 (n=2), @entity882 (n=1), intestinal perforation (n=4), astenia (n=4), @entity448 (n=3), @entity1211 and @entity101 (n=1 each). RR of the 66 pts evaluable by RECIST ( @entity1493 n=27; @entity1493 +CT n=39) was 29%, and RR of the 76 pts by the CA125 marker ( @entity1493 n=37; @entity1493 +CT n=39) was 49%. Greater RRs for the combination vs @entity1493 alone (31% vs 26% and 59% vs 38%) and for non-PR vs PR pts (35% vs 12% and 55% vs 31%) were seen. Med OS from @entity1493 was 14 mo(CI, 9-22), with almost no differences between the combination and @entity1493 alone (15 vs 14). Med OS according to @entity902 -free interval (PFI) was 7.8 mo PR, 22.5 m PPS and 13.6 m for PS. Med PFS from @entity1493 was 4.9 mo (CI, 3.8-6.9). CONCLUSIONS: Antiangiogenic treatment was active and well tolerated in this highly pretreated population. Response rate was higher for the combination group; however, a similar overall survival was observed for the combination treatment and bevacizumab alone.

Bevacizumab alone or with chemotherapy in highly pretreated, relapsed, @entity43 XXXX .

@entity43 :: ('MESH:D010051', 'Disease') :: ['Ovarian Cancer', 'epithelial ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity', 'toxicities'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombopenia'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1493 :: ('12064', 'Species') :: ['BEV'] @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous thromboembolism'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity1945 :: ('MESH:D019772', 'Chemical') :: ['topotecan']
@entity1 :: (9606,Species) :: ['patients']
